Teva Pharmaceuticals has voluntarily recalled approximately 508,220 bottles of several blood pressure medications, including Amlodipine/Valsartan and Amlodipine/Valsartan/Hydrochlorothiazide combination tablets. Laboratory testing confirmed that these products contain an impurity called N-nitrosodimethylamine (NDEA), which is a suspected human carcinogen. These medications are used to treat high blood pressure and were distributed nationwide in various dosage strengths in both 30-count and 90-count bottles.
The medications contain NDEA, an impurity that is classified as a probable human carcinogen and may cause cancer with long-term exposure. Patients are advised not to stop taking their medication without a replacement, as the risk of untreated high blood pressure can be immediate and severe.
Refund and alternative guidance
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.